Systemic treatment in breast cancer: a primer for radiologists

Insights into Imaging

Volumn 7, Issue 1, 2016, Pages 131-144

  Michaels, Aya Y ^a   Keraliya, Abhishek R ^a,b   Tirumani, Sree Harsha ^a,b   Shinagare, Atul B ^a,b   Ramaiya, Nikhil H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Breast cancer; CT; Hormonal therapy; Molecular targeted therapy; MRI

Indexed keywords

EID: 84956488561     PISSN: None     EISSN: 18694101     Source Type: Journal    
DOI: 10.1007/s13244-015-0447-4     Document Type: Review

References (67)

1. (2014) National Clinical Practice Guidelines in Oncology (NCCN guidelines): Breast cancer-version 3.2014. Available via http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site
2. Chikarmane SA, Tirumani SH, Howard SA, Jagannathan JP, DiPiro PJ (2015) Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine. Clin Radiol 70:1–10
3. Jordan VC (2006) Tamoxifen (ici46,474) as a targeted therapy to treat and prevent breast cancer. Br J Pharmacol 147(Suppl 1):S269–S276
4. Rugo HS (2008) The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 19:16–27
5. Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244–254
6. Cataliotti L, Buzdar AU, Noguchi S et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial. Cancer 106:2095–2103
7. Croxtall JD, McKeage K (2011) Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women. Drugs 71:363–380
8. Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the finher trial. J Clin Oncol 27:5685–5692
9. Spielmann M, Roche H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27:6129–6134
10. Kelly CM, Buzdar AU (2013) Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer. Drugs 73:505–515
11. Abdel-Razeq H, Marei L (2011) Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 5:87–94
12. Lin NU, Dieras V, Paul D et al (2009) Multicenter phase ii study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452–1459
13. Swain SM, Kim SB, Cortes J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (cleopatra study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471
14. Zimmerman P, Lu DS, Yang LY, Chen S, Sayre J, Kadell B (2000) Hepatic metastases from breast carcinoma: comparison of noncontrast, arterial-dominant, and portal-dominant phase spiral CT. J Comput Assist Tomogr 24:197–203
15. Sica GT, Ji H, Ros PR (2000) CT and MR imaging of hepatic metastases. AJR Am J Roentgenol 174:691–698
16. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. HER2ean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
17. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
18. He H, Cai C, Charnsangavej C et al (2015) Contrast-enhanced computed tomography evaluation of hepatic metastases in breast cancer patients before and after cytotoxic chemotherapy or targeted therapy. Can Assoc Radiol J. doi:10.1016/j.carj.2015.03.005
19. Lee SL, Chang ED, Na SJ et al (2014) Pseudocirrhosis of breast cancer metastases to the liver treated by chemotherapy. Cancer Res Treat 46:98–103
20. Shinagare AB, Jagannathan JP, Krajewski KM, Ramaiya NH (2013) Liver metastases in the era of molecular targeted therapy: new faces of treatment response. AJR Am J Roentgenol 201:W15–W28
21. Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA (2008) Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology 247:189–196
22. Stattaus J, Hahn S, Gauler T et al (2009) Osteoblastic response as a healing reaction to chemotherapy mimicking progressive disease in patients with small cell lung cancer. Eur Radiol 19:193–200
23. Jung JI, Kim HH, Park SH et al (2004) Thoracic manifestations of breast cancer and its therapy. Radiographics 24:1269–1285
24. Tanaka K, Shimizu K, Ohtaki Y et al (2013) Diagnosis and surgical resection of solitary pulmonary nodules in patients with breast cancer. Mol Clin Oncol 1:117–123
25. Nishino M, Jagannathan JP, Ramaiya NH, Van den Abbeele AD (2010) Revised recist guideline version 1.1: what oncologists want to know and what radiologists need to know. AJR Am J Roentgenol 195:281–289
26. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM (2001) MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 13:868–875
27. Ko ES, Han BK, Kim RB et al (2013) Analysis of factors that influence the accuracy of magnetic resonance imaging for predicting response after neoadjuvant chemotherapy in locally advanced breast cancer. Ann Surg Oncol 20:2562–2568
28. McGuire KP, Toro-Burguete J, Dang H et al (2011) MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18:3149–3154
29. Lobbes M, Prevos R, Smidt M (2012) Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using breast MRI – a review of current knowledge. J Cancer Ther Res 1:34
30. Bottcher J, Hansch A, Pfeil A et al (2013) Detection and classification of different liver lesions: comparison of gd-eob-dtpa-enhanced MRI versus multiphasic spiral CT in a clinical single centre investigation. Eur J Radiol 82:1860–1869
31. Guglielmo FF, Mitchell DG, Gupta S (2014) Gadolinium contrast agent selection and optimal use for body MR imaging. Radiol Clin N Am 52:637–656
32. Lee KH, Lee JM, Park JH et al (2013) MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid. Korean J Radiol 14:894–904
33. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K (2010) Comparison of gadolinium-eob-dtpa-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 20:2690–2698
34. Ringe KI, Husarik DB, Sirlin CB, Merkle EM (2010) Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 195:13–28
35. Thoeny HC, Ross BD (2010) Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 32:2–16
36. Shah R, Vattoth S, Jacob R et al (2012) Radiation necrosis in the brain: imaging features and differentiation from tumor recurrence. Radiographics 32:1343–1359
37. Al-Okaili RN, Krejza J, Wang S, Woo JH, Melhem ER (2006) Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 26(Suppl 1):S173–S189
38. Rousseau C, Devillers A, Sagan C et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage ii and iii breast cancer by [18f]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24:5366–5372
39. Berriolo-Riedinger A, Touzery C, Riedinger JM et al (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34:1915–1924
40. Humbert O, Cochet A, Coudert B et al (2015) Role of positron emission tomography for the monitoring of response to therapy in breast cancer. Oncologist 20:94–104
41. Avril N, Sassen S, Roylance R (2009) Response to therapy in breast cancer. J Nucl Med 50(Suppl 1):55S–63S
42. Chao ST, Suh JH, Raja S, Lee SY, Barnett G (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96:191–197
43. Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH (2011) Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. J Neurooncol 103:137–146
44. Lecouvet FE, Talbot JN, Messiou C et al (2014) Monitoring the response of bone metastases to treatment with magnetic resonance imaging and nuclear medicine techniques: a review and position statement by the HER2ean Organisation for Research and Treatment of Cancer Imaging Group. Eur J Cancer 50:2519–2531
45. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22:2942–2953
46. Malhotra P, Berman CG (2002) Evaluation of bone metastases in lung cancer. Improved sensitivity and specificity of PET over bone scanning. Cancer Control 9(254):259–260
47. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150S
48. Torrisi JM, Schwartz LH, Gollub MJ, Ginsberg MS, Bosl GJ, Hricak H (2011) CT findings of chemotherapy-induced toxicity: what radiologists need to know about the clinical and radiologic manifestations of chemotherapy toxicity. Radiology 258:41–56
49. Cronin CG, O’Connor M, Lohan DG et al (2009) Imaging of the gastrointestinal complications of systemic chemotherapy. Clin Radiol 64:724–733
50. Park SI, Jeon WH, Jeung HJ, Kim GC, Kim DK, Sim YJ (2014) Clinical features of docetaxel chemotherapy-related lymphedema. Lymphat Res Biol 12:197–202
51. Shahab N, Haider S, Doll DC (2006) Vascular toxicity of antineoplastic agents. Semin Oncol 33:121–138
52. Lawson M, Vasilaras A, De Vries A, Mactaggart P, Nicol D (2008) Urological implications of cyclophosphamide and ifosfamide. Scand J Urol Nephrol 42:309–317
53. Swerdlow AJ, Jones ME (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case–control study. J Natl Cancer Inst 97:375–384
54. Fong K, Causer P, Atri M, Lytwyn A, Kung R (2003) Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. Radiographics 23:137–150, discussion 151–135
55. Ochi J, Hayakawa K, Moriguchi Y, Urata Y, Yamamoto A, Kawai K (2010) Uterine changes during tamoxifen, toremifene, and other therapy for breast cancer: evaluation with magnetic resonance imaging. Jpn J Radiol 28:430–436
56. Erman M, Abali H, Oran B et al (2004) Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state? Ann Oncol 15:1622–1626
57. Rodriguez-Frias EA, Lee WM (2007) Cancer chemotherapy II: atypical hepatic injuries. Clin Liver Dis 11:663–676, viii
58. Pilleul F, Chave G, Dumortier J, Scoazec JY, Valette PJ (2005) Fatty infiltration of the liver. Detection and grading using dual T1 gradient echo sequences on clinical MR system. Gastroenterol Clin Biol 29:1143–1147
59. Hadji P, Aapro MS, Body JJ et al (2011) Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol 22:2546–2555
60. ®). Int J Dermatol 53:e159–e160
61. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247
62. Huszno J, Les D, Sarzyczny-Slota D, Nowara E (2013) Cardiac side effects of trastuzumab in breast cancer patients—single center experiences. Contemp Oncol (Pozn) 17:190–195
63. Guarneri V, Lenihan DJ, Valero V et al (2006) Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 24:4107–4115
64. Perez EA, Rodeheffer R (2004) Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322–329
65. Cardinale D, Colombo A, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:3910–3916
66. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684
67. de Azambuja E, Holmes AP, Piccart-Gebhart M et al (2014) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol 15:1137–1146